Insider Shareholders with Direct Ownership of Monte Rosa Therapeutics, Inc. (GLUE)
This section provides a comprehensive overview of the insiders with direct ownership of Monte Rosa Therapeutics, Inc. (GLUE). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Monte Rosa Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
New Enterprise Associates 17, L.P.
> 10% Shareholder |
7,692,298 | 0 | 7,692,298 $43.5 Million | 1 |
Jun 28, 2021
Added 12.01%
|
| 6,515,869 | 2,719,646 | 5,099,336 $28.9 Million | 6 |
Sep 20, 2024
Reduced 18.17%
|
|
|
Markus Warmuth
President & CEO |
128,000 | 0 | 544,538 $3.08 Million | 1 |
Jan 02, 2025
Added 19.03%
|
|
Filip Janku
Chief Medical Officer |
36,000 | 0 | 45,189 $255,769 | 1 |
Jan 02, 2025
Added 44.34%
|
|
Sharon Townson
Chief Scientific Officer |
36,000 | 0 | 36,000 $203,760 | 1 |
Jan 02, 2025
Added 50.0%
|
|
Philip Nickson
Chief Business & Legal Officer |
36,000 | 0 | 36,000 $203,760 | 1 |
Jan 02, 2025
Added 50.0%
|
|
Jennifer Champoux
Chief Operating Officer |
30,000 | 0 | 30,000 $169,800 | 1 |
Jan 02, 2025
Added 50.0%
|
|
Edmund Dunn
Principal Accounting Officer |
11,850 | 2,817 | 25,794 $145,994 | 3 |
Jan 02, 2025
Added 31.48%
|